What happens when creativity and intelligence walk into a bar? The Conversation. This is where the scientific and creative meet to discuss topics in the life science industry intelligently with scientists and medical writers as well as creatively with marketers and business leaders. You will also hear insights from people who care most about improving health outcomes: patients, health care providers, research fellows, and industry leaders. We invite you to join in!
A recent ONS/ONCC study determined the tasks, knowledge, and skills necessary to successfully perform as an oncology nurse navigator.
Read about the findings and see how the role is evolving at voice.ons.org
What we find interesting is the current and anticipated professional development needs that oncology nurse navigators identified, which are focused on the following topics:
Patients’ needs related to survivorship issues
Management of psychosocial issues
Technologies and systems
Financial aspects of care
Metrics and outcome data collection and analysis
Improving communication with patients, caregivers, and healthcare providers
The role of the oncology nurse navigator is evolving and becoming more recognized. With it stresses a greater understanding of who this important audience is, and how to effectively communicate with navigators to meet your business goals and improve patient outcomes.
Life science marketers, nurse educators, and sales representatives who develop ways to help navigators support their patients are valuable and relevant.
Next week, continuing with our nurse navigator series, we’ll give 3 tips for connecting with nurse navigators. Learn more about this emerging, influential audience—sign up below!
Some interesting things happening with pharma and biotech in regulatory intelligence, take a look:
Industry asks FDA to halt new off-label rule. Industry groups PhRMA, BIO, and the Medical Information Working Group have asked the Agency to stop a new rule on off-label promotion that was recently published in the Federal Register. (FiercePharma)
The FDA has lifted a clinical hold imposed last December on Seattle Genetics. After the deaths of four people involved in the studies, the company is now free to continue several trials testing their experimental cancer drug, vadastuximab talirine, for the treatment of acute myeloid leukemia (AML). (Reuters)
Lilly’s psoriasis study meets primary endpoint. Eli Lilly has published impressive results in a study comparing its psoriasis treatment, Taltz, to Johnson & Johnson’s Stelara. (Pharmafile)
Lilly and Chi-Med partner for success in colorectal cancer. Eli Lilly and China MediTech (Chi-Med) have announced positive top-line data in their phase 3 study of fruquintinib in locally advanced or metastatic colorectal cancer. The study, which was conducted in China, involved more than 400 patients. (FierceBiotech)
Karyopharm’s selinexor fails phase 2 study. Karyopharm reported that a phase 2 trial of selinexor in acute myeloid leukemia (AML) failed to show improved overall survival in a study of 176 patients. (FierceBiotech)
“Cancer occurrences are on track to outpace oncology services, hurting patients and doctors alike.”
Hear from a patient’s perspective on this shortage of oncologists that is not going away. Read the full article at www.nytimes.com
Oncology nurse navigators and other expanded audiences (APP, PA, NP, CNS, etc.) are becoming more important and their roles are evolving to take on more responsibilities. These instrumental audiences can step in to help fill the shortage. Pharma marketers should also look to empower them and optimize their role with education and tools, as they can become advocates to start and stay on therapy.
To learn more about nurse navigators and expanded audiences sign up for our series below and Contact Us for effective ways to engage with these influential audiences.
Take a look at some of the events in regulatory intelligence with pharma and biotech this week!
Regeneron, together with Intouch Solutions, has developed and launched a virtual and augmented reality app to allow people to “see” what it’s like to have retinal disease. The app, called “In My Eyes” was originally meant as a sales tool and includes branding for Eylea, but expanded to be used for education with caregivers, patients, and their family and friends. (FiercePharma)
Kite Pharma’s CAR T-cell therapy meets study goal, stating it was shown to be highly effective in the treatment of aggressive non-Hodgkin’s lymphoma. (Reuters)
FDA granted Teva Pharmaceutical Industries priority review for its experimental therapy, SD-809, to treat tardive dyskinesia. Tardive dyskinesia is a disorder marked by uncontrollable movements for which there are no currently approved therapies. (Reuters)
The FDA approved AstraZeneca’s Qtern, a combination of dapagliflozin and saxagliptin, as a supplement to diet and exercise, for the improvement of glycemic control in adults with type-2 diabetes. (Pharmafile)
Roche initiates phase 3 trial in Alzheimer’s disease. Despite failures from similar drugs, Roche announced that the company has begun a second late-stage trial of crenezumab, in partnership with the Swiss biotech company AC immune, the developer of the drug. (Reuters)
“Pharma wants to connect to reach patients, and on the other side, patients are open to connecting with pharma for things like education, information, clinical research and financial help.”
An annual survey, conducted by patient engagement platform Inspire, finds that patients report a broad disconnect with pharma companies. The article discusses some suggestions to engage with patients and build relationships. Read the full article at www.fiercepharma.com.
In our experience working with nurse audiences at Aegis, we believe nurse navigators can help pharma companies be more patient-centric. Nurse navigators are a key source of information and education for patients and an avenue for pharma to connect directly to patients and build a good relationship. In many interviews and discussions with nurse navigators, each of them mentioned needing help from pharma with unbranded patient education and financial resources for patients.
Learn more about who this influential audience is by signing up for our nurse navigator series. And, if you want to create tools and resources that are unbranded and address key topics in patient-friendly language, Contact Us.
Here’s a look at what’s going on in regulatory intelligence with pharma and biotech this week!
Momenta receives a warning letter from FDA. The approval of Momenta’s generic version of Teva’s widely-used multiple sclerosis (MS) drug, Copaxone, is likely to be delayed because the Pfizer plant where the product is being finished received a warning letter from FDA. (FiercePharma)
Ozanimod beats Avonex in a comparative trial. Celgene’s oral multiple sclerosis (MS) treatment, ozanimod, met the primary endpoint of reducing the annualized relapse rate of MS in a Phase 3 trial. Results demonstrated that two different doses of ozanimod showed statistically significant and clinically meaningful improvements compared to Biogen’s Avonex. (Investopedia)
Biosimilar Inflectra matches Remicade’s efficacy in Crohn’s disease (CD). Pfizer and Celltrion released data from a Phase 3 study that demonstrated comparable safety and efficacy between Inflectra and Remicade, meeting the criterion for non-inferiority. (PharmaTimes)
Why Siliq doesn’t have a suffix. The FDA has approved a new biologic, leaving some to question why its name lacks a suffix. Siliq (brodalumab) was licensed under the scope of recently issued guidance on the Nonproprietary Naming of Biological Products. The final guidance was issued on January 12, which did not allow the FDA sufficient time to designate a proper name that includes a suffix. To avoid delay in getting the product to patients, the Agency approved the product sans suffix. (RAPS)
Medtronic launches innovative surgical stapler. Medtronic launched its Signia stapling system, an intelligence-based minimally invasive surgical solution. The Signia stapler adjusts the stapler’s speed based on tissue variability measurements and offers one-handed staple firing. (MassDevice)